leadf
logo-loader
viewGT Biopharma Inc.

GT Biopharma unique technology targeting Lymphoma and Leukemia cell lines

GT Biopharma (OTCQB:GTBP) Dr. Raymond Urbanski sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.  The clinical stage biopharmaceutical company is focused on the development and commercialization of immuno-oncology products based off its proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms.

Quick facts: GT Biopharma Inc.

Price: 0.2 USD

OTCQB:GTBP
Market: OTCQB
Market Cap: $15.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

11 hours, 41 minutes ago

2 min read